About Us

History

Present ~ 2018

  • 2021

    • 09

      Presentation of final data from Phase 1 study of ISU104 at ESMO

    • 07

      The grant of a patent for Barecetamab(ISU104) by the EPO(European Patent Office)

    • 05

      The grant of a patent for Brecetamab(ISU104) by the CNIPA(China National Intellectual Property Administration)

    • 04

      Manufacturing consortium for Russia’s Sputnik V COVID-19 vaccine with GL Rapha and RDIF(Russian Direct Investment Fund)

    • 03

      Publication of data from preclinical study with Barecetamab(ISU104), Molecular Cancer Therapeutics

      Completion of the Phase 1 study of Abcertin®(Australia)

    • 02

      Publication of data from the Phase 1/2 clinical trial of Dalcinonacog alfa(ISU304), Journal of Thrombosis and Haemostasis

      Approval of the International Nonproprietary Name(INN) Barecetamab for ISU104

  • 2020

    • 12

      The grant of a patent for ISU104 by Indonesia DGIP(Directorate General of Intellectual Property)

    • 11

      Out-licenses agreement for ISU305 to Russian pharmaceutical company Pharmasyntez

    • 09

      Clinical data presentation from the Phase 1 Part 2 study of ISU104 at the ESMO

    • 08

      Completion of the Phase 1 clinical trial of ISU305(Australia and New Zealand)

    • 06

      Preclinical data presentation for ISU104 at the AACR

      Presentation of final data from Phase 2 study of ISU304 at the WFH

    • 04

      The grant of a patent for ISU104 by the CIPO(Canadian Intellectual Property Office)

  • 2019

    • 12

      Initiation of the Phase 1 clinical trial for Abcertin®(Australia)

    • 11

      The grant of a patent for ISU104 by Federal Service for Intellectual Property of the Russian Federation, ROSPATENT

    • 09

      Clinical data presentation from the Phase 1 Part 1 study of ISU104 at the ESMO(European Society for Medical Oncology)

    • 07

      The grant of a patent for ISU104 by the USPTO(United States Patent and Trademark Office)

    • 06

      The grant of a patent for ISU104 by the IP Australia

    • 03

      Initiation of the Phase 1 clinical trial for ISU305(Australia and New Zealand)

  • 2018

    • 12

      The grant of a patent for ISU104 by the KIPO

    • 10

      New product launch in Korea: Trintop® for the treatment of Wilson’s disease

    • 05

      Clinical data presentation from the Phase 1/2 study for ISU304 at the WFH(World Federation of Hemophilia)

    • 04

      Preclinical data presentation for ISU104 at the AACR(American Association for Cancer Research)

    • 03

      The grant of a patent for ISU304 by the KIPO(Korean Intellectual Property Office)

      Completion of new GMP manufacturing facility in Yongin, Gyeonnggi

    • 01

      ISU104 is supported and funded by the KDDF(Korea Drug Development Fund).

      The grant of a patent for ISU104 by the TIPO(Taiwan Intellectual Property Office)